Current Osteoporosis Reports最新文献_第2页

Phytocannabinoids and bone health. 植物大麻素和骨骼健康。

IF 5.3 2区医学

Current Osteoporosis Reports Pub Date : 2026-09-08 DOI: 10.1007/s11914-026-00982-1

Hayley Palmer, Diana E Roopchand

{"title":"Phytocannabinoids and bone health.","authors":"Hayley Palmer, Diana E Roopchand","doi":"10.1007/s11914-026-00982-1","DOIUrl":"10.1007/s11914-026-00982-1","url":null,"abstract":"Purpose of the review: Phytocannabinoids have received attention for their therapeutic properties, however, it is unclear how they affect bone homeostasis. Additionally, increased use of cannabis and hemp-derived products have raised questions about their impact on musculoskeletal health. This review summarizes recent studies that investigate the impact of phytocannabinoids on bone.Recent findings: The most well studied phytocannabinoid in relation to bone health is cannabidiol (CBD). In vitro data suggests CBD inhibits osteoclasts and promotes osteoblast activity. Rodent studies have demonstrated CBD may be useful for managing bone loss associated with osteoporosis and periodontitis, as well as reducing fracture pain and promoting healing. Recent studies suggest other phytocannabinoid isolates and extracts containing multiple phytocannabinoids have varying effects on bone. The first clinical study in this area reported that a medical cannabis product reduced markers of bone turnover in healthy adults. Cannabinoids bind to receptors in the endocannabinoid system which is involved in regulation of bone metabolism. Phytocannabinoids may improve bone health; however, additional work is required to determine factors such as the optimal dose, timing, and route of administration.","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":"24 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13553617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148913875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Management of Adverse Skeletal Effects Following Bariatric Surgery Procedures in People Living with Obesity. 修正：肥胖患者减肥手术后骨骼不良反应的处理。

IF 5.3 2区医学

Current Osteoporosis Reports Pub Date : 2026-09-05 DOI: 10.1007/s11914-026-00981-2

Léa Karam, Julien Paccou

引用次数: 0

A Review of Rejuvenation Strategies Targeting Mesenchymal Stem Cell Senescence and Their Impact on Bone Health and Regeneration. 针对间充质干细胞衰老的再生策略及其对骨健康和再生的影响

IF 5.3 2区医学

Current Osteoporosis Reports Pub Date : 2026-08-12 DOI: 10.1007/s11914-026-00977-y

David P Heinrichs, Rebekah M Samsonraj

{"title":"A Review of Rejuvenation Strategies Targeting Mesenchymal Stem Cell Senescence and Their Impact on Bone Health and Regeneration.","authors":"David P Heinrichs, Rebekah M Samsonraj","doi":"10.1007/s11914-026-00977-y","DOIUrl":"10.1007/s11914-026-00977-y","url":null,"abstract":"Purpose of review: The purpose of this article is to emphasize the critical role aging and senescence plays on mesenchymal stem cell (MSC) functionality and its influence on bone health. This review also highlights recent advancements in strategies to rejuvenate senescent MSCs to aid in delaying or preventing age-related illnesses associated with bone loss.Recent findings: Studies have expanded upon many established rejuvenation strategies including senolytic agents, drugs used to selectively eliminate senescent cells, and targeted inhibitors to the secretory profile of senescent cells. New routes for MSC rejuvenation including nanoplatform targets such as biomaterials, nanovesicles, and physical exercise are showing promise for future clinical applications. Ongoing clinical trials are progressing towards rejuvenation therapies that delay age-induced bone loss. This review provides an overview of the current research landscape into rejuvenation of senescent MSCs to combat bone loss due to age and highlights new platforms and strategies for rejuvenation that could have clinical relevance.","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":"24 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13461651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dynamic Assessment of Cortical Porosity in Preclinical Models: Time-lapse Imaging of Cortical Remodeling. 临床前模型中皮质孔隙度的动态评估：皮质重塑的延时成像。

IF 5.3 2区医学

Current Osteoporosis Reports Pub Date : 2026-08-10 DOI: 10.1007/s11914-026-00980-3

Fatma M Younis, Kim Harrison, Xuan Wei, Lisbeth Koch Thomsen, Amine Lagzouli, Peter Pivonka, David M L Cooper

{"title":"Dynamic Assessment of Cortical Porosity in Preclinical Models: Time-lapse Imaging of Cortical Remodeling.","authors":"Fatma M Younis, Kim Harrison, Xuan Wei, Lisbeth Koch Thomsen, Amine Lagzouli, Peter Pivonka, David M L Cooper","doi":"10.1007/s11914-026-00980-3","DOIUrl":"10.1007/s11914-026-00980-3","url":null,"abstract":"Purpose of the review: A decade has passed since we published a review entitled: \"Cortical Bone Porosity: What Is It, Why Is It Important, and How Can We Detect It?\" (Curr.Osteoporos.Rep. 2016;14(5):187 - 98), which addressed the growing shift from bone mass to microarchitecture in osteoporosis research. It culminated in a brief examination of animal models of cortical bone porosity and the potential of using imaging to dynamically track cortical remodeling. Here we reflect on a decade of progress in this research space - preclinical time-lapse imaging of cortical pores/remodeling. Our objectives are to: (1) review time-lapse micro-CT imaging of bone microarchitecture in murine models; (2) overview of the development of synchrotron propagation phase contrast micro-CT imaging to track cortical porosity/remodeling in rabbits; and (3) discuss challenges and future directions.Recent findings: Despite first being demonstrated over 20 years ago, time-lapse micro-CT of trabecular bone in preclinical models has been relatively limited. Synchrotron imaging of rabbits has recently enabled the first time-lapse views of individual cortical remodeling events and associated findings have included linear erosion rates (LER) of remodeling spaces consistent with values inferred in classic canine studies, diverse and complex remodeling space morphologies particularly in parathyroid hormone-dosed animals where LER is also reduced, and disruption of linear advance in glucocorticoid-dosed animals. Time-lapse imaging of animal models holds tremendous potential to shed new light on the dynamic process of cortical remodeling as well as related diseases and the efficacy of their treatments.","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":"24 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osteocyte-vascular Interactions in Bone Physiology and Pathology. 骨生理学和病理学中的骨细胞-血管相互作用。

IF 5.3 2区医学

Current Osteoporosis Reports Pub Date : 2026-08-05 DOI: 10.1007/s11914-026-00978-x

Léa Gellée, Delphine B Maurel

{"title":"Osteocyte-vascular Interactions in Bone Physiology and Pathology.","authors":"Léa Gellée, Delphine B Maurel","doi":"10.1007/s11914-026-00978-x","DOIUrl":"10.1007/s11914-026-00978-x","url":null,"abstract":"Purpose of review: Through their extensive lacuno-canalicular network, osteocytes act as key regulators of bone remodelling and have more recently been recognized as contributors to bone repair. However, these processes occur in a highly vascularized tissue, and the relationship between osteocytes and bone vasculature remains poorly understood. This review summarizes current knowledge on osteocyte-vascular interactions, with a focus on communication mechanisms and their relevance to bone physiology, aging, and disease.Recent findings: Emerging evidence indicates that osteocyte-vascular communication occurs through several modalities. Indirect signalling involves paracrine factors secreted by osteocytes, including VEGF, sclerostin, neuropeptide Y, as well as extracellular vesicles, which modulate ECs' behaviour. Direct communication has also been suggested through physical interactions between osteocytes and blood vessels, including mitochondrial transfer and potentially gap junctions. Recent studies have also identified lymphatic vessels within bone, raising the possibility of previously unrecognized interactions between osteocytes and the lymphatic vasculature. Together, these findings highlight diverse modes of communications and associated signalling pathways, through which osteocytes may regulate vascular function within bone. Despite emerging insights into osteocyte-bone vasculature crosstalk, the underlying mechanisms remain incompletely understood. Advances in experimental tools may improve our knowledge of this bidirectional dialogue, providing new perspectives on bone physiology, skeletal pathologies, and potential therapeutic strategies targeting this interaction.","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":"24 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13442514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148680523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of Chronic Hypoparathyroidism and Hyperparathyroidism in Pregnancy/Lactation. 妊娠/哺乳期慢性甲状旁腺功能减退和甲状旁腺功能亢进的处理。

IF 5.3 2区医学

Current Osteoporosis Reports Pub Date : 2026-08-01 DOI: 10.1007/s11914-026-00979-w

Stefan Pilz, Daniel Arian Kraus, Lisa Schmitt, Miriam Meister, Christina M Berr, Maria P Yavropoulou, Uwe Riedmann

{"title":"Management of Chronic Hypoparathyroidism and Hyperparathyroidism in Pregnancy/Lactation.","authors":"Stefan Pilz, Daniel Arian Kraus, Lisa Schmitt, Miriam Meister, Christina M Berr, Maria P Yavropoulou, Uwe Riedmann","doi":"10.1007/s11914-026-00979-w","DOIUrl":"10.1007/s11914-026-00979-w","url":null,"abstract":"Purpose of review: We summarize and discuss evidence on management of chronic hypoparathyroidism (HypoPT) and primary hyperparathyroidism (PHPT) in pregnancy and lactation to provide guidance for clinical care.Recent findings: Women with HypoPT are at increased risk of certain pregnancy complications, though most pregnancies are uncomplicated. Conventional therapy with activated vitamin D and calcium is continued throughout pregnancy, but there are unpredictable changes in the required dosages warranting regular surveillance during pregnancy (e.g., all 3 to 4 weeks). Data on parathyroid hormone (PTH) replacement therapy in pregnancy are limited, but a few case reports suggest favourable outcomes with this treatment. During lactation, dosage requirements for conventional therapy of HypoPT are often reduced and usually normalize again after weaning. In women with PHPT, surgical treatment should be pursued before conception. PHPT is not associated with adverse pregnancy outcomes in women with mild hypercalcemia but maternal and fetal complications significantly increase with higher calcium concentrations. There is no clear threshold for this risk increase, but several studies and expert groups support a cut-off concentration of about 2.85 mmol/L in albumin-adjusted calcium and 1.45 mmol/L in ionized calcium. For pregnant women with PHPT and calcium above these cut-off concentrations, parathyroidectomy, preferentially in the second trimester, is recommended. Medical treatment for hypercalcaemic PHPT is limited and requires individual decision making. Immediately after delivery, hypercalcemia may worsen in women with PHPT. Clinical care of women with HypoPT and PHPT in pregnancy and lactation requires intensive surveillance and consideration of the specific changes in bone and mineral metabolism during these times.","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":"24 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13428684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148654720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 5.3 2区医学

Current Osteoporosis Reports Pub Date : 2026-07-25 DOI: 10.1007/s11914-026-00976-z

Gabriella Moraes Rae, Kara Walisser, Tanveer Towheed, Jonathan D Adachi

{"title":"Similarities and Differences Between Three North American Treatment Guidelines for the Management of Osteoporosis.","authors":"Gabriella Moraes Rae, Kara Walisser, Tanveer Towheed, Jonathan D Adachi","doi":"10.1007/s11914-026-00976-z","DOIUrl":"10.1007/s11914-026-00976-z","url":null,"abstract":"Purpose of review: This review compares three major North American osteoporosis guidelines: the American Association of Clinical Endocrinology (AACE), the Bone Health and Osteoporosis Foundation (BHOF), and the Osteoporosis Canada Clinical Practice Guideline (OCCPG). The paper evaluates differences in fracture risk assessment, diagnostic strategies, pharmacologic treatment recommendations, and follow-up approaches to determine how each guideline supports osteoporosis management and fracture prevention.Recent findings: Recent research supports anabolic therapies for patients at high fracture risk. Studies show these agents improve bone mineral density and reduce fracture rates, especially when followed by antiresorptive therapy. Emerging evidence also supports sequential treatment strategies and individualized risk assessment to optimize outcomes. All three guidelines emphasize fracture prevention and early diagnosis but differ in risk thresholds, use of FRAX, and recommendations for newer therapies. Current evidence suggests anabolic-first approaches may improve outcomes in high-risk patients. Future research should focus on long-term safety, comparative effectiveness, and personalized treatment strategies.","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":"24 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148594257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Short-Chain Fatty Acids and Derived Metabolites in Osteoporosis. 短链脂肪酸及其衍生代谢产物在骨质疏松症中的作用。

IF 5.3 2区医学

Current Osteoporosis Reports Pub Date : 2026-07-24 DOI: 10.1007/s11914-026-00975-0

Guanghong Qiu, Sihui Xie, Wenjia Luo, Kangping Yang, Jiaqiang Wu, Xianhuan Zhou, Shiqi Li, Yufan Hu, Liang Yang

{"title":"The Role of Short-Chain Fatty Acids and Derived Metabolites in Osteoporosis.","authors":"Guanghong Qiu, Sihui Xie, Wenjia Luo, Kangping Yang, Jiaqiang Wu, Xianhuan Zhou, Shiqi Li, Yufan Hu, Liang Yang","doi":"10.1007/s11914-026-00975-0","DOIUrl":"10.1007/s11914-026-00975-0","url":null,"abstract":"Purpose of review: To investigate the role of short-chain fatty acids (SCFAs) in the pathogenesis of osteoporosis and their potential value as therapeutic targets.Recent findings: Recent studies have shown that SCFAs, metabolic products of gut microbiota, play a crucial regulatory role in bone remodeling. SCFAs achieve this by activating G protein-coupled receptors (GPCRs), inhibiting histone deacetylases (HDACs), and regulating signaling pathways involved in bone metabolism. This effectively suppresses osteoclast activity, reduces bone resorption, enhances osteoblast function, and alleviates oxidative stress, thereby promoting bone formation. These findings not only reveal the key mechanisms by which SCFAs maintain bone metabolic homeostasis but also highlight their potential for treating osteoporosis in the elderly and postmenopausal women. Related clinical trials and drug research are currently underway. This review explores the potential value and theoretical basis of targeting SCFAs for the prevention and treatment of osteoporosis, summarizes existing clinical trials and related drug research, and provides new directions for developing future treatment strategies.","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":"24 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148580744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When X Does Not Mark the Spot: Autosomal Dominant and Recessive Forms of Renal Hypophosphatemic Rickets and Osteomalacia. 当X不标记点：常染色体显性和隐性形式的肾低磷佝偻病和骨软化症。

IF 5.3 2区医学

Current Osteoporosis Reports Pub Date : 2026-07-07 DOI: 10.1007/s11914-026-00963-4

Carlos R Ferreira, Erik A Imel

{"title":"When X Does Not Mark the Spot: Autosomal Dominant and Recessive Forms of Renal Hypophosphatemic Rickets and Osteomalacia.","authors":"Carlos R Ferreira, Erik A Imel","doi":"10.1007/s11914-026-00963-4","DOIUrl":"10.1007/s11914-026-00963-4","url":null,"abstract":"Purpose of review: Conditions resulting in elevated fibroblast growth factor 23 (FGF23) cause hypophosphatemic rickets and osteomalacia. The most common of these is X-linked hypophosphatemia. In this review we will broadly discuss the other less common and clinically distinct forms of renal hypophosphatemia, with a focus on the autosomal dominant and autosomal recessive types.Recent findings: Variants in multiple genes cause dominant (FGF23, SGK3, FGFR1), recessive (DMP1, ENPP1, FAM20C, INPPL1) or even somatic (NRAS, HRAS, GNAS, gene fusions) conditions of FGF23 excess, with important phenotypic differences. For example, in autosomal dominant hypophosphatemic rickets due to FGF23 variants, iron deficiency drives the phenotype, while ENPP1 variants cause phenotypes ranging from severe neonatal vascular calcifications to rickets or osteoporosis. Other gene abnormalities cause FGF23-independent hypophosphatemia, often involving kidney disease. Recognizing the different mechanisms and phenotypes of hypophosphatemic conditions is critical to prognosis, management and to developing more effective therapies.","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":"24 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13341720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148399832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond Fracture Probability: Communicating the Full Consequences of Fracture and Contextualization. 超越骨折概率：沟通骨折和情境化的全部后果。

IF 5.3 2区医学

Current Osteoporosis Reports Pub Date : 2026-06-30 DOI: 10.1007/s11914-026-00974-1

Tuan V Nguyen

{"title":"Beyond Fracture Probability: Communicating the Full Consequences of Fracture and Contextualization.","authors":"Tuan V Nguyen","doi":"10.1007/s11914-026-00974-1","DOIUrl":"10.1007/s11914-026-00974-1","url":null,"abstract":"Purpose of review: Fracture risk calculators such as FRAX, the Garvan Fracture Risk Calculator, and QFracture are now embedded in clinical guidelines, yet they communicate only a single numerical probability. This review examines whether current tools adequately meet patients' informational needs and identifies critical gaps in fracture risk communication.Recent findings: Most patients want fracture risk information, but only approximately half actually receive it. Research consistently shows that patients globally prefer visual over numerical formats, yet existing tools do not communicate the consequences of fracture, including mortality, subsequent fracture risk, and loss of independence, nor do they contextualise risk within available treatment options. Three critical gaps are identified: the consequence gap (what fracture means for survival and function), the controllability gap (how treatment modifies risk), and the format gap (how risk is presented and understood). Moving fracture risk communication beyond a single number requires integrating consequence, context, and format. The digital platform BONEcheck addresses these gaps by incorporating mortality risk, refracture risk, skeletal age, treatment contextualisation, and multi-format presentation including icon arrays. Future research, clinical practice, and guideline development should prioritise a more complete, actionable, and patient-centred approach to fracture risk communication.","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":"24 1","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148354256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0